DefiniGEN’s mission is to develop and deliver cell model solutions which can significantly benefit the drug discovery and regenerative medicine sectors. We collaborate on various academic, medical and pharmaceutical organizations to deliver this vision.
EBiSC https://www.ebisc.org/ is Europe’s largest stem cell consortium comprising 31 partners including eight global pharmaceutical companies (Pfizer, Astra Zeneca, UCB, J&J, Lundbeck, Novo Nordisk, Eli Lilly and Bayer). The EBiSC iPS cell bank acts as a central storage and distribution facility for human iPS cells, used by researchers across academia and industry in the study of disease and the development of new therapeutics.
DefiniGEN’s role is to validate EBiSC iPS cell lines by generating liver hepatocyte cells for toxicology, disease modelling, and regenerative medicine applications.